Supplemented and unsupplemented tissue sealants, methods of their production and use
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-035/14
A61K-031/74
A61F-002/28
출원번호
US-0465860
(2003-06-20)
발명자
/ 주소
MacPhee,Martin J.
Drohan,William N.
Liau,Gene
Nunez,Hernan
Burgess,Wilson H.
Maciag,Thomas
Singh,Manish
출원인 / 주소
The American National Red Cross
대리인 / 주소
Sterne, Kessler, Goldstein, &
인용정보
피인용 횟수 :
11인용 특허 :
92
초록▼
This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, a
This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.
대표청구항▼
What is claimed is: 1. A method of localized sustained delivery of a supplement to promote generation or regeneration of bone and/or cartilage, said method comprising: (a) preparing a biocompatible, supplemented tissue sealant composition comprising: (i) at least one supplement selected from the gr
What is claimed is: 1. A method of localized sustained delivery of a supplement to promote generation or regeneration of bone and/or cartilage, said method comprising: (a) preparing a biocompatible, supplemented tissue sealant composition comprising: (i) at least one supplement selected from the group consisting of a cytotoxin or cell proliferation inhibiting compound, an osteogenic compound, an osteo-conductive compound, a cartilage inducing compound, an oligonucleotide or polynucleotide, a compound that inhibits the differentiation of cells involved in the formation or metabolism of bone, a compound that induces the differentiation of cells involved in the formation or metabolism of bone, and a compound that prevents resorption of bone, in an amount which promotes generation or regeneration of bone and/or cartilage; and (ii) fibrinogen, or a derivative or metabolite thereof selected from the group consisting of fibrin I and fibrin II, in an amount which forms a fibrin matrix in the presence of thrombin and Ca+ + and water; and (b) applying said composition of step (a) to a site in need of newly formed bone and/or cartilage under conditions which induce formation of a fibrin matrix at a concentration which provides sustained delivery of an amount of said supplement effective to promote the generation or regeneration of bone and/or cartilage, wherein said amount of said supplement is greater than the amount which is soluble in said fibrin matrix; and wherein said fibrin matrix provides a scaffold that determines the shape and location of said newly formed bone and/or cartilage; and further wherein said sustained delivery is for a period greater than the period obtained according to simple diffusion kinetics. 2. A method of localized sustained delivery of a supplement to promote generation or regeneration of bone and/or cartilage, said method comprising: (a) preparing a biocompatible, supplemented tissue sealant composition comprising: (i) at least one growth factor supplement in an amount which promotes generation or regeneration of bone and/or cartilage; and (ii) fibrinogen, or a derivative or metabolite thereof selected from the group consisting of fibrin I and fibrin II, in an amount which forms a fibrin matrix in the presence of thrombin and Ca+ + and water; and (b) applying said composition of step (a) to a site in need of newly formed bone and/or cartilage under conditions which induce formation of a fibrin matrix at a concentration which provides sustained delivery of an amount of said growth factor supplement effective to promote the generation or regeneration of bone and/or cartilage; wherein said fibrin matrix provides a scaffold that determines the shape and location of said newly formed bone and/or cartilage; and further wherein said sustained delivery is for a period greater than the period obtained according to simple diffusion kinetics. 3. A method of localized sustained delivery of a supplement to promote generation or regeneration of bone and/or cartilage, said method comprising: (a) preparing a biocompatible, supplemented tissue sealant composition comprising: (i) at least one supplement selected from the group consisting of an osteogenic protein, an osteoconductive protein, a cartilage inducing protein, a polypeptide, a hormone, a cytokine, a cytotoxin or cell proliferation inhibiting protein, a protein that inhibits the differentiation of cells involved in the formation or metabolism of bone, a protein that induces the differentiation of cells involved in the formation or metabolism of bone, and a protein that prevents resorption of bone, in an amount which promotes generation or regeneration of bone and/or cartilage; and (ii) fibrinogen, or a derivative or metabolite thereof selected from the group consisting of fibrin I and fibrin II, in an amount which forms a fibrin matrix in the presence of thrombin and Ca+ + and water; and (b) applying said composition of step (a) to a site in need of newly formed bone and/or cartilage under conditions which induce formation of a fibrin matrix at a concentration which provides sustained delivery of an amount of said supplement effective to promote the generation or regeneration of bone and/or cartilage; wherein said fibrin matrix provides a scaffold that determines the shape and location of said newly formed bone and/or cartilage; and further wherein said sustained delivery is for a period greater than the period obtained according to simple diffusion kinetics. 4. The method of claim 1, wherein said supplement is an oligonucleotide or polynucleotide. 5. The method of claim 1, wherein said supplement is a cytotoxin or cell proliferation inhibiting compound. 6. The method of claim 1, wherein said supplement is an osteogenic compound or a cartilage inducing compound. 7. The method of claim 2, wherein said supplement is a lipid or liposome. 8. The method of claim 3, wherein said growth factor is selected from the group consisting of: fibroblast growth factors; platelet-derived growth factors; insulin-binding growth factors; epidermal growth factors; transforming growth factors; cartilage-inducing factors; osteoid-inducing factors; osteogenin; bone growth factors; id="DEL-S-00001" date="20060919" bone morphogenetic growth factors;id="DEL-S-00001" collagen growth factors; and heparin-binding growth factors. 9. The method of claim 8, wherein said biocompatible, supplemented tissue sealant composition further comprises at least one regulatory compound selected from the group consisting of inhibiting compounds and potentiating compounds, wherein said inhibiting compounds inhibit biochemical activities of one or more factors interfering with a biological function of said supplement, while said potentiating compounds potentiate and/or mediate biological activity of said supplement. 10. The method of claim 9, wherein said regulatory compound potentiates and/or mediates the biological activity of said supplement, while simultaneously inhibiting the biochemical activity of one or more factors that interfere with the biological activity of said supplement. 11. The method of claim 9, wherein said regulatory compound is heparin. 12. The method of claim 9, wherein said regulatory compound interacts with said supplement and/or said fibrin matrix, such that degradation of said fibrin matrix is reduced. 13. The method of claim 3, wherein said supplement is a cytokine. 14. The method of claim 3, wherein said supplement is a hormone. 15. The method of claim 3, wherein said supplement is a polypeptide. 16. The method of claim 3, wherein said supplement is an osteogenic protein, an osteoconductive protein or a cartilage inducing protein. 17. The method of claim 16, wherein said osteogenic protein, osteoconductive protein or cartilage inducing protein is selected from the group consisting of cartilage-inducing factors; osteoid-inducing factors; osteogenin; bone growth factors which modulate the proliferation, migration and/or attraction of progenitor bone cells; id="DEL-S-00002" date="20060919" bone morphogenetic growth factors; demineralized bone matrix;id="DEL-S-00002" and interleukin. id="DEL-S-00003" date="20060919" 18. The method of claim 1, 2 or 3, wherein said biocompatible, supplemented tissue sealant composition further comprises a polysaccharide selected from the group consisting of chitin, chitosan and N,O-carboxymethyl chitosan.id="DEL-S-00003" 19. The method of claim 1, 2 or 3, wherein said biocompatible, supplemented tissue sealant composition is applied to a biomaterial. 20. The method of claim 19, wherein said biomaterial is an indwelling medical device. 21. The method of claim 19, wherein said biomaterial is a resorbable biomaterial. 22. The method of claim 21, wherein said resorbable biomaterial is selected from the group consisting of hydroxyapaptite, coral and collagen. 23. The method of claim 19, wherein said biomaterial is a non-resorbable biomaterial. 24. The method of claim 23, wherein said non-resorbable biomaterial is steel or titanium. 25. The method of claim 1, 2 or 3, wherein said supplement is in solid form. 26. The method of claim 1, 2 or 3, wherein said supplement is introduced in solution in a carrier, said carrier having a higher rate of dissolution or diffusion in said fibrin matrix than said supplement, so that said supplement is deposited within said fibrin matrix as a solid precipitate. 27. The method of claim 1, 2 or 3, wherein said supplement is introduced as an emulsion. 28. The method of claim 1, 2 or 3, wherein said supplement interacts with said fibrin matrix and/or said environment of use, such that degradation of said fibrin matrix is reduced. 29. The method of claim 28, wherein said supplement interacts with the body fluids and/or cells of the patient. 30. The method of claim 29, wherein said interaction is pH dependent. 31. The method of claim 1, 2 or 3, wherein said supplement is first dissolved in a carrier which is then introduced as an emulsion. 32. The method of claim 31, wherein said carrier is a lipid. 33. The method of claim 32, wherein said carrier is a lipid-based structure. 34. The method of claim 1, 2 or 3, wherein said biocompatible tissue sealant composition further comprises thrombin. 35. The method of claim 34, wherein said thrombin is recombinantly-produced human thrombin. 36. The method of claim 1, 2 or 3, wherein said biocompatible tissue sealant composition further comprises Factor XIII. 37. The method of claim 36, wherein said Factor XIII is recombinantly-produced human Factor XIII. 38. The method of claim 1, 2 or 3, wherein said biocompatible tissue sealant composition further comprises Ca++. 39. The method of claim 1, 2 or 3, wherein said fibrinogen is recombinantly-produced human fibrinogen. 40. The method of claim 1, 2 or 3, wherein said biocompatible, supplemented tissue sealant composition further comprises an effective amount of at least one additional supplement selected from the group consisting of an analgesic, an anesthetic, an antimicrobial compound, an antibiotic, an antibody, an anticoagulant, an antifungal agent, an anti-inflammatory compound, an antiparasitic agent, an antiseptic compound, an antiviral compound, a cardiovascular drug, a cytokine, a cytotoxin or cell proliferation inhibiting compound, a chemotherapeutic drug, a growth factor, a hormone, an interferon, a lipid or liposome, an oligonucleotide or polynucleotide, an osteogenic compound, a cartilage inducing compound, a polysaccharide, a protease inhibitor, a proteoglycan, a polypeptide, a steroid, a vasoconstrictor, a vasodilator, a vitamin, a nutritional supplement, and a mineral. 41. The method of claim 1, 2 or 3, wherein said site in need of newly formed bone and/or cartilage is a site in a mammalian body. 42. The method of claim 1, 2 or 3, wherein said fibrinogen, or derivative or metabolite thereof, forms a fibrin matrix prior to step (b). 43. The method of claim 1, 2 or 3, wherein said fibrinogen, or derivative or metabolite thereof, forms a fibrin matrix after step (b). 44. The method of claim 1, 2 or 3, wherein said fibrinogen, or derivative or metabolite thereof, forms a fibrin matrix during step (b). 45. The method of claim 1, 2 or 3, wherein said composition of step (a) is dried prior to step (b). 46. The method of claim 45, wherein said fibrin matrix is lyophilized prior to step (b). 47. The method of claim 45, wherein said fibrin matrix is dried prior to step (b). 48. The method of claim 1, 2 or 3, wherein said composition of step (a) is lyophilized prior to step (b).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (92)
Redl Heinz (Vienna ATX) Habison Georg (Vienna ATX), Apparatus for applying a tissue adhesive.
Redl Heinz (Vienna ATX) Schlag Gnther (Vienna ATX) Pridun Nestor (Vienna ATX), Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation.
Juergensen Kay (Murten CHX) Aeschlimann Daniel (Basel CHX) Hunziker Ernst B. (Riedholz CHX), Biological adhesive composition and method of promoting adhesion between tissue surfaces.
Drohan William N. ; MacPhee Martin J. ; Miekka Shirley I. ; Singh Manish S. ; Elson Clive,CAX ; Taylor ; Jr. John R., Chitin hydrogels, methods of their production and use.
Errede Louis A. (North Oaks MN) Stoesz James D. (St. Paul MN) Winter ; deceased George D. (late of St. Paul MN by Jenny Upton ; personal representative), Composite wound dressing.
Burnouf-Radosevich Miryana (Wavrin FRX) Burnouf Thierry (Wavrin FRX), Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof.
Brown Ross G. (Terre Haute IN) Bright David R. (Terre Haute IN) Williams Robert D. (Terre Haute IN), Fibrin binder/carrier for active biochemical agents.
Edwardson Peter A. D.,GBX ; Fairbrother John E.,GBX ; Gardner Ronald S.,GBX ; Hollingsbee Derek A.,GBX ; Cederholm-Williams Stewart A.,GBX, Fibrin sealant compositions and methods for utilizing same.
Wahlig Helmut (Darmstadt DEX) Dingeldein Elvira (Dreieich DEX) Kirchlechner Richard (Rott a. Inn DEX) Orth Dieter (Darmstadt DEX) Rogalski Werner (Alsbach DEX), Flavonoid phosphate salts of aminoglycoside antibiotics.
Ron Eyal (Lexington MA) Schaub Robert G. (Pelham NH) Turek Thomas J. (Boston MA), Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
Weiner Alan L. (Plainsboro NJ) Lenk Robert P. (Lambertville NJ) Carpenter-Green Sharon S. (Cranbury NJ) Fountain Michael W. (Plainsboro NJ), Localized delivery using fibronectin conjugates.
Gristina Anthony G. (Reston VA) Myrvik Quentin N. (Caswell Beach NC), Method and compositions for the direct concentrated delivery of passive immunity.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Williams Stuart K. (Drexel Hill PA) Jarrell Bruce E. (Philadelphia PA), Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surfa.
Cotter Darlene L. (Fox Lake IL) Abry Barbara L. (Mundelein IL) Weigand Ray A. (Libertyville IL), Method of using tissue and cell adhesive preparations for biological test systems.
Edwardson Peter A. D.,GBX ; Fairbrother John E.,GBX ; Gardner Ronald S.,GBX ; Hollingsbee Derek A.,GBX ; Cederholm-Williams Stewart A.,GBX, Nondynamic fibrin monomer on bandages, sutures, prostheses and dressings.
Heimburger Norbert (Marburg DEX) Fuhge Peter (Lahntal DEX) Ronneberger Hansjrg (Marburg DEX), One-component tissue adhesive and a process for the production thereof.
Wahlig Helmut (Darmstadt DEX) Dingeldein Elvira (Dreieich DEX) Rothe Johannes (Rossdorf DEX) Stille Wolfgang (Frankfurt DEX), Process for implanting a medicament depot.
Bui-Khac Trung (Montreal CAX) Lavoie Lise (St-Eustache CAX) Michel St Picq Dominique (Ste-Genevive CAX), Process for the obtention of a biological adhesive made of concentrated coagulation factors by “salting-out”.
Zimmermann Eberhard (Mnster-Nienberge DEX) Stroetmann Michael (Mnster DEX), Resorptive sheet material for closing and healing wounds and method of making the same.
MacPhee Martin James ; Drohan William Nash ; Liau Gene ; Haudenschild Christian, Supplemented and unsupplemented tissue sealants, method of their production and use.
MacPhee Martin James ; Drohan William Nash ; Lasa ; Jr. Carlos I.,PHX ; Liau Gene ; Haudenschild Christian, Supplemented and unsupplemented tissue sealants, methods of their production and use.
Bass Lawrence S. (Little Neck NY) Libutti Steven K. (Lido Beach NY) Eaton Alexander M. (New York NY), Tissue bonding and sealing composition and method of using the same.
Tse Daphne C. ; Mankarious Samia S. ; Liu Shu Len ; Thomas William R. ; Alpern Melaine ; Enomoto Stanley T. ; Garanchon Cataline M., Topical fibrinogen complex.
Luck Edward E. (Menlo Park CA) Brown Dennis M. (Menlo Park CA), Treatments employing drug-containing matrices for introduction into cellular lesion areas.
Luck Edward E. (Menlo Park CA) Brown Dennis M. (Menlo Park CA), Treatments employing drug-containing matrices for introduction into cellular lesion areas.
Antoniades Harry N. (Newton MA) Lynch Samuel E. (Jamaica Plain MA) Williams Ray C. (Arlington MA), Wound healing and bone regeneration using PDGF and IGF-I.
Basore, Bob O.; Neumann, William L.; Dorshow, Richard B.; Rajagopalan, Raghavan, Tissue sealant compositions, vascular closure devices, and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.